DSM Biologics to Produce Antibody for MorphoSys

DSM Biologics, a unit of DSM, says it has signed a biopharmaceutical manufacturing agreement with biotech firm MorphoSys (Martinsried, Germany). The deal calls for DSM to develop and manufacture MOR202, a fully human antibody for the treatment of multiple myeloma, at its facility in Groningen, Netherlands. Financial terms were not disclosed. Sproll: Continuing the PER.C6 platform. DSM will use the PER.C6 technology platform of biotech firm Crucell (Leiden, Netherlands). PER.C6 has been developed for large-scale manufacturing of biopharma products including...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers